P
Palvella Therapeutics
Rare disease biopharmaceutical company
About Palvella Therapeutics
Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a clinical-stage biopharmaceutical firm, established in 2015, operating from Wayne, Pennsylvania. The company was founded by Wesley H. Kaupinen, who currently serves as President and CEO, leveraging over two decades of experience in life sciences as both an executive and investor in rare diseases. His background includes roles at Insmed, a biopharmaceutical company focused on rare diseases, and Quaker Partners, a life sciences venture capital firm, which informs Palvella's strategy.
The company focuses on developing and commercializing therapies for severe, rare genetic skin diseases that currently have no FDA-approved treatments. This patient-centric model involves close collaboration with patient advocacy groups to accelerate clinical development. In December 2024, Palvella became a publicly traded company on the Nasdaq Capital Market under the ticker "PVLA" following a merger with Pieris Pharmaceuticals. The transaction, along with a concurrent private placement, is expected to fund operations into the second half of 2027.
Palvella's core business revolves around its patented QTORIN™ platform, a technology developed to overcome the challenges of delivering topical treatments, like rapamycin, deep into the skin layers while minimizing systemic absorption. The company's business model is that of a pre-revenue clinical-stage entity, with its financial structure centered on R&D investments, strategic partnerships, and potential future product sales. A key milestone was receiving a grant from the FDA's Orphan Products Grants Program to support its Phase 3 trial, a significant non-dilutive funding event.
The lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel. This high-strength, room-temperature stable formulation is designed to target the overactivated mTOR pathway, which is implicated in several rare skin diseases. The gel is currently in late-stage clinical trials for two primary indications: a Phase 3 trial (SELVA) for microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial (TOIVA) for cutaneous venous malformations (cutaneous VMs). QTORIN™ rapamycin has received multiple supportive designations from the FDA, including Breakthrough Therapy, Orphan Drug, and Fast Track for microcystic LMs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2024
Open roles
Palvella Therapeutics in the Radnor Township ecosystem
The Palvella Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Food and Drug Administration
Series A1 investor entered at this stage
Ligand Pharmaceuticals
Series B and later10 investors entered at this stage
CAM Capital
Samsara BioCapital
BioAdvance
Agent Capital
Nolan Capital
BVF Partners
Adams Street Partners- OMOpaleye Management
- PEPetrichor
Gore Range Capital
Source: Dealroom Talent Intelligence.
Patents
26 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Palvella Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
FDA accepts Palvella's QTORIN rapamycin NDA with Priority Review for rare skin disease
Palvella lands third FDA grant year for QTORIN rapamycin after Phase 3 win
Palvella completes FDA submission for first-ever treatment for microcystic lymphatic malformations